FDA To Study Selenium Health Claim Consumer Perceptions
This article was originally published in The Tan Sheet
Executive Summary
The agency plans to study whether label claim language for selenium misleads consumers on the benefits of the ingredient. Legal experts say with the proposed study, FDA seeks to influence possible regulations down the road and circumvent court rulings that have curbed the agency’s authority to limit supplement claims.
You may also be interested in...
Trade Groups Defend Qualified Health Claims Following Critical GAO Report
Dietary supplement industry stakeholders are defending the use of qualified health claims, which came under fire in a Government Accountability Office report on shortcomings in FDA's food labeling enforcement
People In Brief
Herbalife brings on Dentali as botanical sciences VP; NACDS expands Nicholson’s role; Innophos announces interim CFO; George Hamilton new face of Infusion Life Sciences; Aker BioMarine names sales VP; Atteryd to chair Food Supplements Europe.
FDA Details “Quality Agreements” For Marketers, Contract Manufacturers
The “Contract Manufacturing Arrangements for Drugs: Quality Agreements” draft guidance describes how parties involved in contract manufacturing of drugs can employ quality agreements to delineate their responsibilities and ensure drug quality, safety and efficacy.